key: cord-0741243-gve6d03a
authors: Gao, Zhao; Zhang, Lin; Ma, Julia; Jurado, Andrea; Hong, Seon-Hui; Guo, Ju-Tao; Rice, Charles M.; MacDonald, Margaret R.; Chang, Jinhong
title: Development of antibody-based assays for high throughput discovery and mechanistic study of antiviral agents against yellow fever virus
date: 2020-08-14
journal: Antiviral Research
DOI: 10.1016/j.antiviral.2020.104907
sha: d6b38b3c2e21802b3ff2e9ef43f072347470f534
doc_id: 741243
cord_uid: gve6d03a

Abstract Despite the availability of a highly effective yellow fever virus (YFV) vaccine, outbreaks of yellow fever frequently occur in Africa and South America with significant mortality, highlighting the pressing need for antiviral drugs to manage future outbreaks. To support the discovery and development of antiviral drugs against YFV, we characterized a panel of rabbit polyclonal antibodies against the three YFV structural proteins and five non-structural proteins and demonstrated these antibody reagents in conjunction with viral RNA metabolic labeling, double-stranded RNA staining and membrane floatation assays as powerful tools for investigating YFV polyprotein processing, replication complex formation, viral RNA synthesis and high throughput discovery of antiviral drugs. Specifically, the proteolytic processing of the viral polyprotein can be analyzed by Western blot assays. The predominant nuclear localization of NS5 protein as well as the relationship between intracellular viral non-structural protein distribution and foci of YFV RNA replication can be revealed by immunofluorescence staining and membrane flotation assays. Using an antibody against YFV NS4B protein as an example, in-cell western and high-content imaging assays have been developed for high throughput discovery of antiviral agents. A synergistic antiviral effect of an YFV NS4B-targeting antiviral agent BDAA and a NS5 RNA-dependent RNA polymerase inhibitor (Sofosbuvir) was also demonstrated with the high-content imaging assay. Apparently, the antibody-based assays established herein not only facilitate the discovery and development of antiviral agents against YFV, but also provide valuable tools to dissect the molecular mechanism by which the antiviral agents inhibit YFV replication.

Yellow fever is a mosquito-borne disease caused by yellow fever virus (YFV) infection and frequently associated with a severe form of hemorrhagic fever and liver injury with jaundice leading to a mortality rate of up to 60% (Monath and Vasconcelos, 2015) . YFV infection can be prevented by the attenuated 17D vaccine and its derivatives (Klitting et al., 2018a; Klitting et al., 2018b) . The combination of vector-control and vaccination campaigns has significantly reduced the incidence of YFV infection in the human population. However, the virus remains in a sylvatic cycle between mosquito vectors and nonhuman primates and can occasionally transmit to humans through mosquito bites. This results in tremendous difficulty to manage the disease, not only at individual and local levels, but also globally. Concern has been raised regarding the possibility of yellow fever taking hold in previously unaffected and unvaccinated parts of the world such as Asia, where host, vector, and climatic conditions could conspire to promote YFV dissemination.

In 2016, there were urban yellow fever outbreaks in Angola and Democratic Republic of Congo, which resulted in vaccine shortage and emergent vaccination campaigns using only onefifth of the regular vaccine dosage in high-risk populations (Calisher and Woodall, 2016) . In late 2017 and early 2018, there was another urban outbreak in Brazil. While the number of yellow fever cases are significantly underreported due to the undeveloped nature of many endemic areas, it is estimated that up to 1.7 million YFV infections occur in Africa each year resulting in 29,000-60,000 deaths . This outnumbers the estimated death toll of global dengue virus infection (http://www.who.int/mediacentre/factsheets/fs100/en/). The World Health Organization and its partners responded to these recent outbreaks of yellow fever and emphasized the importance of additional research and the development of new vaccines, J o u r n a l P r e -p r o o f diagnostics and therapeutics as countermeasures (http://www.who.int/emergencies/yellowfever/response/en/). While improvement of vaccines and vaccination policy remains the best strategy to control global yellow fever endemics and epidemics, it is anticipated that other yellow fever outbreaks will occur in the near future. Therefore, it is crucial to develop safe and highly efficacious antiviral strategies against YFV infection that can be used not only for treating infected patients, but also for the prophylactic treatment of individuals potentially exposed to YFV, since sufficient post-vaccination immunity requires at least a week to develop Gaucher et al., 2008; Querec et al., 2009 ). Moreover, a safe antiviral therapy would be invaluable for visitors to endemic/epidemic regions who cannot safely take the attenuated vaccine (e.g., seniors and immunocompromised individuals). Presently, there is no antiviral drug available for the treatment and/or prevention of yellow fever (Beasley et al., 2015; Julander, 2013) .

Over the past decades, tremendous industrial and academic efforts have been made toward the discovery and development of vaccines and antiviral agents against emerging flaviviruses such as dengue virus (DENV), Japanese encephalitis virus (JEV), and Zika virus (ZIKV) (Lim et al., 2013) . However, research on the molecular virology and pathogenesis of YFV, as well as development of novel vaccines and antiviral agents, have lagged largely due to the unrealistic assumption that current vaccination strategies would be sufficient to prevent and ultimately eliminate the disease. Improving yellow fever management through the development of effective therapeutics will require in-depth understanding of the molecular biology and pathogenesis of YFV, knowledge of which remains surprisingly limited given YFV's medical significance.

J o u r n a l P r e -p r o o f Like other flaviviruses, YFV has a single positive-strand RNA genome approximately 11 kb in length with a 5' cap but no 3'-polyA tail. The genome encodes a polyprotein that is cotranslationally processed by viral and host cellular proteases into three structural proteins (i.e., capsid (C), membrane (prM/M), envelope (E)) and seven non-structural (NS) proteins (i.e., NS1, NS2A, NS2B, NS3, NS4A, NS4B, NS5) Lescar et al., 2018) . Few reagents and research tools, particularly the antibodies against YFV proteins, are available for investigating the molecular mechanism of YFV replication and pathogenesis. Currently, the commercially available YFV antibodies are only limited to the envelope and NS1 proteins. A couple of epitope-mapped monoclonal antibodies specific for YFV envelope or NS1 protein were reported, but have not been made available commercially (Adungo et al., 2016; Ricciardi-Jorge et al., 2017) . Polyclonal antibodies against capsid and NS1 have been developed as well, which were proposed for use in YFV research and for the development of novel diagnostic tests (Stock et al., 2015) . Taking advantage of the recently available rabbit polyclonal antibodies against all three YFV structural proteins and five of the seven non-structural proteins (i.e., NS1, NS2B, NS3, NS4B and NS5) from GeneTex, Inc., we established several antibody-based assays and demonstrated their utility, in conjunction with viral RNA metabolic labeling, double stranded RNA staining and membrane floatation assays, in molecular and cellular analyses of viral proteins and RNA synthesis in YFV infection, antiviral drug discovery and mechanistic studies.

J o u r n a l P r e -p r o o f Vero cells were purchased from ATCC. Huh-7 and Huh-7.5 cells (Blight et al., 2002) were cultured in DMEM, 10% fetal bovine serum (FBS), 1X non-essential amino acid (NEAA).

The 293TLR3/IFNβLuc cell line was established based on HEK293 (ATCC) with reconstituted TLR3 as well as an interferon β promotor driven luciferase, as previously described (Guo et al., 2014) . Yellow fever virus 17D strain was generated from a cDNA clone, pACNR/FLYF-17Dx (Bredenbeek et al., 2003; Guo et al., 2016; Rice et al., 1985) . Yellow fever virus Asibi strain was generated from a slightly modified version of plasmid pACNR-FLYF-Asibi (Yi et al., 2011) , designated pACNR-2015FLYF-Asibi, the sequence of which has been deposited to GenBank (MT093734). The modifications were based on a comparison of the plasmid sequence to that of Asibi sequences available in GenBank and included three nucleotide changes (nucleotide 6013 was changed from C to T, 6829 from T to C, and 8008 from C to T) to more accurately reflect the Asibi sequence.

All the YFV protein-specific rabbit polyclonal IgG antibodies were provided by GeneTex, Inc. These antibodies were raised by immunizing rabbits with synthetic peptides or recombinant proteins (Table 1 ). The antibodies were purified from rabbit sera by antigen-affinity chromatography. Anti-Flavivirus Group Antigen antibody 4G2 was purchased from EMD Millipore. J2 double-stranded RNA (dsRNA) mouse monoclonal antibody was purchased from 

YFV 17D infected cells were lysed with 1× NuPAGE™ LDS Sample Buffer (Invitrogen) containing 2.5% β-mercaptoethanol. YFV Asibi infected cells were lysed with 1× NuPAGE™ LDS Sample Buffer containing 5% β-mercaptoethanol, and the lysates were heat-inactivated at 70°C for 15 minutes. Proteins in the cell lysates were separated on a NuPAGE Novex 4-12% Bis-Tris gel (Invitrogen) and electrophoretically transferred onto a nitrocellulose membrane (Invitrogen). The membranes were blocked with TBST containing 5% nonfat dry milk and probed with the indicated YFV antibodies at 1:1000 dilution. The bound antibodies were visualized with IRDye secondary antibodies (IRDye 800CW Goat anti-Rabbit IgG and IRDye 680RD Goat anti-Mouse IgG) and by imaging with the LI-COR Odyssey system. Mouse monoclonal antibody against β-actin was used as a loading control. A pre-stained protein size marker was purchased from Bio-Rad.

Huh-7 cells were seeded on round coverslips (Neuvitro Corporation) in 24-well plates and infected with YFV at 1 multiplicity of infection (MOI) for 24 h. The cells were either fixed with 3.5% paraformaldehyde in PBS at room temperature for 20 min, or 95% ethanol and 5% glacial acetic acid at -20˚C for 10 min, followed by permeabilization with 1% Triton X-100.

After blocking with 10% FBS and 2% BSA in PBS for 1 h, the cells were incubated with the corresponding primary antibodies at 4°C overnight. Subsequently, the cells were washed three J o u r n a l P r e -p r o o f times with 0.1% Tween-20 in PBS (PBST) and stained with secondary antibodies. Cell nuclei were counterstained with 4',6-diamidine-2'-phenylindole dihydrochloride (DAPI) purchased from Sigma-Aldrich. Finally, the coverslips were placed on glass slides with ProLong Gold Antifade Mountant (ThermoFisher Scientific). Images were sequentially acquired on an FV1000 confocal microscope with a PlanApoN 60×/1.42 numerical aperture objective (Olympus). 

Huh-7 cells were seeded on round coverslips (Neuvitro Corporation) in 24 well plate and infected with YFV at 1 MOI. At 24 h post infection, cells were treated with 20 µM actinomycin D for 2 h to inhibit the cellular DNA directed RNA transcription, followed by incubation with 1 mM 5-ethynyl uridine (EU; Invitrogen) in the presence of actinomycin D for 1 h. The nascent RNA labeled with EU were visualized by using the Click-iT™ RNA Alexa Fluor™ 594 Imaging Kit (Invitrogen, C10330). Briefly, after fixing cells with 3.5% paraformaldehyde and permeabilization with 1% Triton X-100, "click" reaction between Alexa Fluor labeled azide and EU modified RNA was performed in accordance to the manufacturer's instructions. Images were J o u r n a l P r e -p r o o f acquired on an FV1000 confocal microscope (Olympus) with a PlanApoN 60×/1.42 numerical aperture objective (Olympus).

YFV infected cells grown in 60-mm dishes were washed, scraped into PBS, and collected by centrifugation at 500 × g for 10 min. After resuspension in 250 μl hypotonic buffer (10 mM Tris-HCl [pH 7.8], 10 mM NaCl) and swelling (15 min on ice), the cells were disrupted by passing through a 27-gauge needle for 25 times. After centrifugation at 900 × g for 5 min at 4°C, the supernatant was mixed with 1.82 ml 72% (wt/wt) sucrose in low-salt buffer (LSB; 50mM

Tris-HCl [pH 7.5], 25mM KCl, 5mM MgCl 2 ) and overlaid with 2.27 ml of 55% (wt/wt) sucrose in LSB, followed by 0.68 ml of 10% (wt/wt) sucrose in LSB. The sucrose gradient was centrifuged at 46,000 rpm in a Beckman Coulter SW55 ultracentrifuge rotor for 16 h at 4°C. Ten equal volume (500 μl) fractions were taken sequentially from the top of the gradient. In some experiment, after the primary membrane floatation, the ER-membrane-enriched fraction was collected and divided into equal volume and treated with 1% n-dodecyl β-D-maltoside (DDM; Invitrogen) or 1% digitonin (Promega) for 1 h at 4°C with rotation. The samples were then mixed with 72% sucrose in LSB and overlaid sequentially with 55% and 10% sucrose to form the gradient and centrifuge as described above. Proteins were precipitated from each fraction by adding 4 volumes of methanol followed by centrifugation at 12,000 × g for 10 min. Detection of viral and host proteins in each fraction in a Western blot assay was described in section 2.3.

J o u r n a l P r e -p r o o f Huh-7 cells were seeded in 96-well plates overnight and infected with YFV at a MOI of 1. At 48 h post-infection, cells were fixed as previously described (Guo et al., 2016; Yu et al., 2012) and probed with YFV NS4B (GTX134030), NS3 (GTX133959) antibodies or anti-Flavivirus Group Antigen antibody 4G2 at 1:1000 dilution. IRDye® 800CW Goat anti-Mouse IgG (LI-COR) or IRDye® 800CW Goat anti-Rabbit IgG were used as secondary antibodies at 1:2000 dilution. Cell viability was determined with DRAQ5 from Biostatus and Sapphire700 from LI-COR. Images and data analysis were obtained using LI-COR Odyssey.

293TLR3/IFNβLuc cells were cultured in 96-well black well plates overnight and infected with YFV at a MOI of 0.1. At 48 h post-infection, luciferase activity was analyzed by using an equal volume of luciferase substrate, as previously described (Guo et al., 2014) .

Huh-7 cells were cultured in 24-well plates overnight and infected with YFV at a MOI of 1. At 48 h post-infection, total cellular RNA was extracted using TRIzol Reagent (Thermo Fisher Scientific). YFV RNA was detected in a quantitative reverse transcription-PCR (qRT-PCR) assay using a LightCycler 480II apparatus (Roche). β-actin mRNA served as internal control. Primer sequences are as described previously (Guo et al., 2016) .

Huh-7 cells were cultured in 96 or 384-well plates overnight and infected with YFV at the indicated MOI. At 48 h post-infection, cells were fixed with 4% paraformaldehyde and J o u r n a l P r e -p r o o f probed with YFV NS4B antibody (GTX134030) at 1:500 dilution. Alexa Fluor Goat anti-Rabbit 594 IgG (H+L) was used as secondary antibody at 1:300. Cell nuclei were stained with DAPI

(1:1000). Nine fields per well in 96-well plate, or six fields per well in 384-well plate were taken and analyzed using CellInsight CX7 High-Content Screening Platform (ThermoFisher) to calculate average percent of NS4B positive cells or total immunofluorescence intensity.

Z' factor (Z') was calculated using the following equation: Z'=1-((3δ p +3δ n )/|μ p -μ n |), where μ p and μ n are mean values of positive control and negative control, respectively; δ p and δ n are the standard deviations of positive and negative control, respectively (Zhang et al., 1999) . Zscore was calculated using the following equation: Z-score= (t-μ n )/ δ n , where t is value of each test well. Other high-throughput screening parameters were determined as described (Liu et al., 2017) . P values were calculated using two-tailed Student's t-test. Synergy effect was evaluated using MacSynergy II (Prichard et al., 1993; Prichard and Shipman, 1996) .

A panel of antibodies against all three YFV structural proteins and five of the seven nonstructural proteins, including NS1, NS2B, NS3, NS4B and NS5, raised by immunization of rabbits with synthetic peptides or recombinant viral proteins, had become commercially available from GeneTex, Inc.. The reactivity of these antibodies was initially confirmed by western blot assays using either recombinant protein or whole cell lysates of 293T cells transiently transfected J o u r n a l P r e -p r o o f with a plasmid expressing individual YFV protein, corresponding to the originally used immunogens (https://www.genetex.com). In this study, these ten YFV antibodies were further validated by western blot assays using cell lysates from YFV 17D-infected Vero cells. As shown in Fig. 1A , for the eight antibodies against YFV capsid, NS1, NS2B, NS3, NS4B or NS5, each detected a single predominant protein species with the expected molecular weight of the corresponding structural or non-structural YFV proteins, only in the YFV-infected cell lysate.

Each of the two NS1 antibodies, generated by using recombinant proteins encompassing a sequence within either the center or C-terminal region of YFV NS1 protein, detected a protein species with the same electrophoretic mobility. Similarly, the two NS3 antibodies, generated by using synthetic peptides encompassing a sequence within either the C-terminus or center region of YFV NS3 protein, also showed comparable sensitivity and specificity in detecting NS3

protein with approximately 69kD. On the contrary, the YFV envelope antibody revealed not only a specific band of approximately 50kD in YFV-infected cell lysates, but also a cross-reacting band that overlaps the β-actin signal in both YFV-infected and uninfected cell lysates, raising concerns for its specificity in recognizing YFV envelope protein in certain assays. The other situation of detecting multiple bands in Western blot assay was observed when prM antibody was used, which only occurred in YFV-infected cells. It is known that immature flaviviral virions bud into the lumen of the endoplasmic reticulum (ER) and mature in the trans-Golgi network with acidic pH during transportation toward the cell surface (Li et al., 2008) . This involves the cleavage of prM protein by cellular furin protease into the "pr" peptide and the M protein (Stadler et al., 1997) . Accordingly, the membrane protein of YFV should exist as both Sequence alignment of YFV 17D (X03700.1) and a wild-type Asibi strain (KF769016.1) indicated that there are 99% overall homology between the coding region of the two strains. Of the YFV proteins the set of antibodies raised against, the lowest homology is 97.6% in envelope protein, and the highest homology is 100% in capsid protein. To test whether the antibodies can also recognize the corresponding proteins of wild-type YFV, Huh-7.5 cells were infected with YFV Asibi strain at a MOI of 2.5 for 40 hrs. Flow cytometry using 4G2 antibody indicated that 47% of cells were infected (data not shown). Western blot assays using the cell lysates from uninfected and the wild-type YFV infected Huh-7.5 cells showed that similar to that observed in YFV 17D infected cells, all the antibodies specifically recognized the corresponding wild-type YFV proteins (Fig. 1B) .

Next, we examined the ability of these YFV antibodies to detect the corresponding viral proteins in YFV-infected cells using an indirect immunofluorescence assay. Six of the ten antibodies, including the antibodies against envelope, prM, NS1 (GTX134025), NS2B, NS3 (GTX133959), and NS4B, specifically detected individual YFV proteins after the cells were fixed with 3.5% paraformaldehyde and permeabilized with 1% Triton X-100 ( Fig. 2A) . Two of the antibodies against capsid or NS5 proteins were able to specifically detect the corresponding YFV proteins when the cells were fixed with 95% ethanol and 5% glacial acetic acid (Fig. 2B ).

All these antibodies displayed a distinct staining pattern that was not seen in uninfected cells.

Two additional antibodies against NS1 (GTX134026) and NS3 (GTX133958)) failed to detect YFV proteins in YFV-infected cells under the immunofluorescence assay conditions described above. Both of the antibodies were generated using immunogens encompassing sequences in the C-termini of NS1 or NS3, indicating neither of them was exposed under the experimental conditions.

The flavivirus genome replication takes place in the vesicles formed by ER membrane rearrangement induced by the membrane-associated viral nonstructural proteins such as NS4A and NS4B. This process was investigated primarily in DENV-infected cells (Miller et al., 2007; Welsch et al., 2009; Zmurko et al., 2015) . We used Huh-7 cells infected with YFV at a MOI of 1 for 24 h so that only a fraction of the cultured cells was infected. An immunofluorescence assay was performed to detect the subcellular localization of the various YFV proteins using confocal microscopy. As shown in Fig. 3 , similar to what was reported for DENV-infected cells, antibodies against the YFV NS proteins (NS1, NS2B, NS3, NS4B) revealed dot-like cytoplasmic structures located in the perinuclear area of infected cells (Miller et al., 2007; Miller et al., 2006; Yi et al., 2012) . Furthermore, each of the non-structural proteins co-localized with doublestranded RNAs (dsRNAs) (Fig. 3) , the putative viral RNA replication intermediates that localize in the replication-hosting vesicles derived from the ER membrane (Welsch et al., 2009; Yi et al., 2011) . Previous electron tomography studies of DENV-infected cells revealed that newly synthesized viral RNAs bud through vesicle pores and release of virion particles into the ER J o u r n a l P r e -p r o o f lumen occurs in the vicinity of the vesicles (Welsch et al., 2009) . Therefore, if a similar replication mechanism holds true for YFV, it is not surprising that some of the dsRNAs also colocalize with structural proteins. An exception is NS5, which, in agreement with previous reports in DENV-infected cells (Miller et al., 2006) , localized predominantly in the nuclei of YFVinfected cells. Consistent with its RNA polymerase function, electron tomography has identified DENV NS5 protein also localized in the cytoplasmic vesicles, the presumed sites of flavivirus RNA replication. However, the cytoplasmic DENV NS5 protein is barely detectable by immunofluorescence staining due to its relatively low levels and poor accessibility (Kumar et al., 2013) . Similarly, cytoplasmic YFV NS5 protein was also undetectable by the polyclonal YFV NS5 antibody (Fig. 3) .

In order to detect viral RNA synthesis in situ in infected cells, the nascent viral RNA can also be metabolically labeled by incorporation of unnatural nucleosides, such as 5-ethynyl-20uridine (EU), and detected by a click chemistry reaction (Jao and Salic, 2008) . This assay allows for the visualization of viral RNA replication foci and determine their spatial relationship with viral and cellular proteins. As shown in Fig. 4A , upon the suppression of cellular RNA synthesis by actinomycin D treatment that specifically inhibits DNA-dependent RNA transcription, the RNA-dependent viral RNA synthesis can be specifically detected only in the cytoplasm of YFV infected cells. As anticipated, the cytosolic EU click signals, or the newly synthesized viral RNA, colocalized with NS4B protein (Fig. 4B) . Although the click chemistry technologies have been used for studying RNA-dependent viral RNA synthesis in the cells infected with Ebolavirus (Hoenen et al., 2012) , chikungunya virus (Reid et al., 2015) or coronavirus (Hagemeijer et al., 2012) , this is the first demonstration that this technology can also be used to visualize flaviviral RNA synthesis in infected cells. In conjunction with the immunofluorescent detection of viral J o u r n a l P r e -p r o o f nonstructural proteins, the click chemical visualization of intracellular viral RNA synthesis may not only reveal viral and host cellular proteins at viral RNA replication foci, but also provide a powerful tool for in situ analyses of viral RNA replication and its inhibition by antiviral drugs.

Like many positive-stranded RNA viruses, flaviviruses replicate their genomes in the ERmembrane-derived vesicles and assemble progeny virions at ER or ER-Golgi intermediate compartment (ERGIC) membranes. It is, therefore, conceivable that investigating the distribution and interaction of viral proteins and host cellular components at the distinct intracellular membrane compartments is essential to understanding the mechanism of flaviviral genome replication and its inhibition by antiviral agents. To analyze the association of viral and cellular proteins with intracellular membranes, we utilized a membrane flotation assay to separate membrane associated proteins and investigate their interactions with cellular lipids and proteins by a membrane flotation assay through sucrose density gradient ultracentrifugation. As described in Section 2.6 in detail, YFV-infected cells were lysed mechanically in a hypotonic buffer without detergent to preserve cell membranes. The cell lysate was loaded at the bottom of the gradient, overlaid with the lower densities of sucrose solutions. The cellular membranes floated up during the ultracentrifugation to the gradients equivalent to their own density. At the completion of centrifugation, ten equal volume fractions were collected from the top of gradient.

The membrane identity and associated proteins in each fraction were analyzed by Western blot assay with antibodies against organelle markers or viral and cellular proteins of interest. As shown in Fig. 5A , as anticipated, viral NS2B, NS4B and envelope proteins were enriched with the ER membrane marker calnexin in fraction 2. Furthermore, treatment of the ER membranes J o u r n a l P r e -p r o o f (fraction 2 from the experiment presented in Fig. 5A ) with a strong detergent completely disrupted the ER membrane and YFV NS2B, NS4B and envelope proteins were solubilized and distributed into fractions with soluble proteins (Fig. 5B) , However, treatment of the ER membranes with the mild detergent digitonin only partially disrupted the membrane and a portion of the viral proteins were still associated with the detergent-resistant membrane structure, presumably lipid rafts, while the vast majority of viral proteins were solubilized under this condition (Fig. 5C ). This is consistent with our previous finding that YFV non-structural proteins, presumed to be associated with the replication complex, were associated with detergent resistant membranes (Yi et al., 2012) . The lipid rafts-associated viral proteins have been shown to play distinct role in viral genome replication and virion particle morphogenesis at the ER. As has been demonstrated in HCV infected cells, further analysis of YFV viral and host proteinprotein interaction in each of these fractions in presence of different detergents, will allow for determination of direct protein interaction or interactions relying on detergent resistant membrane (Boyer et al., 2019) . Such study will shed light on the mechanism of virus replication as well as virion morphogenesis in association with various cellular membranes.

The cytopathic effect (CPE)-based cell viability assay, quantification of viral RNA by real time RT-PCR assay, and the plaque-based yield reduction assay are classical analytic tools for quantitative determination of YFV replication and yields (de Freitas et al., 2019; Guo et al., 2016; Liu et al., 2017) . A YFV replicon that expresses Renilla luciferase in a replicationdependent manner was also employed for antiviral compound screening (Patkar et al., 2009 ).

Recently, we developed an interferon β promotor-driven-luciferase reporter assay for indirect J o u r n a l P r e -p r o o f quantification of viral RNA replication and discovery of antiviral drugs, including YFV (Guo et al., 2014; Ma et al., 2018) .

In this study, we modified and/or developed antibody based quantitative YFV antiviral assays. Using two of the YFV antibodies, we modified an in-cell western assay to detect YFV replication, an assay we previously established using the pan-flavivirus envelope antibody 4G2 to detect DENV, ZIKV, and YFV (Guo et al., 2016; Yu et al., 2012) with simultaneous staining of viable cells. As shown in Fig. 6A , the YFV-specific antiviral compound, 2-((S)-3-((S)-secbutyl)-7-chloro-2-265 oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)acetic acid (designated as BDAA) (Guo et al., 2016) dose-dependently inhibited YFV infection as judged by a significantly reduced fluorescence intensity revealed by the YFV NS3 and NS4B antibodies with similar result. The same assay was also performed with the 4G2 panflavivirus antibody in parallel, which demonstrated a comparable dose-dependent response with BDAA treatment.

Furthermore, a High-Content Imaging (HCI) assay was also established with YFV NS4B antibody-based immunofluorescence staining in combination with image analysis and processing using a CellInsight CX7 High-Content Screening Platform (ThermoFisher). The assay allows for the detection of host cells with DAPI staining as well as with YFV NS4B signal, and automatically analyzes nine fields per sample in 96-well format or six fields per sample in 384well format. Thus, we can determine the total number of cells and the number of NS4B-positive cells from two images of the same field. Fig. 6B shows representative images and the dosedependent reduction of NS4B-positive signals following the treatment with antiviral compound BDAA. Fig. 6C shows a quantitative analysis of the images (average of six fields per well in the 384-well plate) using percentage cells with NS4B signal or total immunofluorescence intensity.

The two types of analyses reveal a similar dose-dependent response with BDAA treatment.

Next, we validated these two antibody-based antiviral assays by directly comparing them with other well-described assays. As shown in Table 2 , similar EC 50 and EC 90 values were obtained using the in-cell western and HCI assays when compared to the interferon β promotor reporter assay, qRT-PCR assay, or yield reduction assay. Each of the previously reported assays has limitations. The interferon β promotor assay can be influenced by innate immune modulatory activity in addition to antiviral activity, while the reliability of the qRT-PCR assay can be affected by viral strain diversity. The yield reduction assay is labor-intensive. These two new YFV antibody based antiviral assays are thus additional tools to quantitatively analyze the molecular events occurring during YFV replication. They should accelerate the discovery of antiviral agents for all the druggable targets, including not only viral components but also cellular factors required for viral replication.

The HCI assay was also evaluated for its performance as a high-throughput screening platform. As shown in Fig. 7A , while mock-treated wells have z-scores ranging from +2 to -2, the wells treated with BDAA have scores in the range of -8 to -9. Furthermore, using BDAA as a positive control and mock-treated cells as a negative control, the assay has a Z' of 0.74 in YFVinfected Huh-7 cells in a 96-well format. The results suggest that the HCI assay using the YFV NS4B antibody can serve as a high-throughput antiviral screening assay with a cutoff z-score value of -3. As an application of performing the HCI assay in HTS format, we tested the synergistic effect of BDAA that targets YFV NS4B protein and Sofosbuvir, a known nucleoside analog that inhibits YFV NS5 RNA-dependent RNA polymerase. The experiment was performed A pre-stained protein molecular weight marker, shown on the left, is used to estimate the size of proteins resolved by gel electrophoresis. The band expected for each of the YFV proteins is indicated on the right.

Huh-7 cells were seeded on 24-well plates and infected with YFV 17D at a MOI of 5 for 24 h.

The cells were either fixed with 3.5% paraformaldehyde in PBS at room temperature for 20 min and permeabilized with 1% Triton X-100 (A), or 95% ethanol and 5% glacial acetic acid at -20°C for 10 min (B). After blocking, the cells were incubated with the indicated primary rabbit polyclonal antibody (NS1 was detected with GTX134025, and NS3 was detected GTX133959)

and Alexa Fluor Goat anti-Rabbit 594 IgG (H+L) secondary antibody. Cell nuclei were counterstained with DAPI. Mock-infected cells serve as negative controls. Images were captured by confocal microscopy using a 20× objective.

J o u r n a l P r e -p r o o f 

Development and Characterization of Monoclonal Antibodies to Yellow Fever Virus and Application in Antigen Detection and IgM Capture Enzyme-Linked Immunosorbent Assay

Yellow fever virus: genetic and phenotypic diversity and implications for detection, prevention and therapy

Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication

Endoplasmic Reticulum Detergent-Resistant Membranes Accommodate Hepatitis C Virus Proteins for Viral Assembly

A stable full-length yellow fever virus cDNA clone and the role of conserved RNA elements in flavivirus replication

Yellow Fever-More a Policy and Planning Problem than a Biological One

Yellow fever virus is susceptible to sofosbuvir both in vitro and in vivo

Yellow Fever Virus: Knowledge Gaps Impeding the Fight Against an Old Foe

Selective expansion of myeloid and NK cells in humanized mice yields human-like vaccine responses

A Novel Benzodiazepine Compound Inhibits Yellow Fever Virus Infection by Specifically Targeting NS4B Protein

An interferon-beta promoter reporter assay for high throughput identification of compounds against multiple RNA viruses

Visualizing coronavirus RNA synthesis in time by using click chemistry

Inclusion bodies are a site of ebolavirus replication

Exploring RNA transcription and turnover in vivo by using click chemistry

Experimental therapies for yellow fever

What Does the Future Hold for Yellow Fever Virus? (II)

What Does the Future Hold for Yellow Fever Virus? (I)

Nuclear localization of dengue virus nonstructural protein 5 does not strictly correlate with efficient viral RNA replication and inhibition of type I interferon signaling

The Dengue Virus Replication Complex: From RNA Replication to Protein-Protein Interactions to Evasion of Innate Immunity

The flavivirus precursor membrane-envelope protein complex: structure and maturation

Ten years of dengue drug discovery: progress and prospects

A cell-based high throughput screening assay for the discovery of cGAS-STING pathway agonists

Enhancing the antiviral potency of ER alpha-glucosidase inhibitor IHVR-19029 against hemorrhagic fever viruses in vitro and in vivo

The nonstructural protein 4A of dengue virus is an integral membrane protein inducing membrane alterations in a 2K-regulated manner

Subcellular localization and membrane topology of the Dengue virus type 2 Non-structural protein 4B

Yellow fever

Identification of inhibitors of yellow fever virus replication using a replicon-based high-throughput assay

MacSynergy II. Version 1.0. User's manual

Analysis of combinations of antiviral drugs and design of effective multidrug therapies

Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans

Sphingosine kinase 2 is a chikungunya virus host factor co-localized with the viral replication complex. Emerg Microbes Infect 4, e61

Nucleotide sequence of yellow fever virus: implications for flavivirus gene expression and evolution

Proteolytic activation of tick-borne encephalitis virus by furin

Development and characterization of polyclonal peptide antibodies for the detection of Yellow fever virus proteins

Composition and three-dimensional architecture of the dengue virus replication and assembly sites

Identification and characterization of the host protein DNAJC14 as a broadly active flavivirus replication modulator

Flavivirus replication complex assembly revealed by DNAJC14 functional mapping

Design, Synthesis, and Biological Evaluation of N-Alkylated Deoxynojirimycin (DNJ) Derivatives for the Treatment of Dengue Virus Infection

A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays

A toggle switch controls the low pHtriggered rearrangement and maturation of the dengue virus envelope proteins

Flaviviral NS4b, chameleon and jack-in-the-box roles in viral replication and pathogenesis, and a molecular target for antiviral intervention